DE60323973D1 - Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd - Google Patents

Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd

Info

Publication number
DE60323973D1
DE60323973D1 DE60323973T DE60323973T DE60323973D1 DE 60323973 D1 DE60323973 D1 DE 60323973D1 DE 60323973 T DE60323973 T DE 60323973T DE 60323973 T DE60323973 T DE 60323973T DE 60323973 D1 DE60323973 D1 DE 60323973D1
Authority
DE
Germany
Prior art keywords
lycanes
glycosamino
copd
heparin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60323973T
Other languages
English (en)
Inventor
Janis Kay Shute
Mary Patricia Carroll
Conway Joy H Dr
Peter Morey Hockey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ockham Biotech Ltd Swanwick Hampshire Gb
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27739233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60323973(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0203830A external-priority patent/GB0203830D0/en
Priority claimed from GB0203773A external-priority patent/GB0203773D0/en
Priority claimed from GB0211414A external-priority patent/GB0211414D0/en
Priority claimed from GB0224330A external-priority patent/GB0224330D0/en
Application filed by University of Southampton filed Critical University of Southampton
Application granted granted Critical
Publication of DE60323973D1 publication Critical patent/DE60323973D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DE60323973T 2002-02-18 2003-02-14 Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd Expired - Lifetime DE60323973D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0203830A GB0203830D0 (en) 2002-02-18 2002-02-18 Improving drug delivery to the respiratory tract
GB0203773A GB0203773D0 (en) 2002-02-18 2002-02-18 Improving drug delivery to the respiratory tract
GB0211414A GB0211414D0 (en) 2002-05-17 2002-05-17 Treatment of respiratory disorders
GB0224330A GB0224330D0 (en) 2002-10-18 2002-10-18 Treatment of respiratory disorders
PCT/GB2003/000663 WO2003068187A1 (en) 2002-02-18 2003-02-14 Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd

Publications (1)

Publication Number Publication Date
DE60323973D1 true DE60323973D1 (de) 2008-11-20

Family

ID=27739233

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323973T Expired - Lifetime DE60323973D1 (de) 2002-02-18 2003-02-14 Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd

Country Status (10)

Country Link
EP (1) EP1511466B2 (de)
AT (1) ATE410147T1 (de)
AU (1) AU2003207317A1 (de)
CA (1) CA2516318C (de)
DE (1) DE60323973D1 (de)
DK (1) DK1511466T4 (de)
ES (1) ES2315479T5 (de)
HK (1) HK1074582A1 (de)
PT (1) PT1511466E (de)
WO (1) WO2003068187A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7560444B2 (en) 2003-10-01 2009-07-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
WO2012073025A1 (en) * 2010-11-30 2012-06-07 Vectura Limited Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
JP7334983B2 (ja) 2018-01-11 2023-08-29 エンフィスィーマ ソリューションズ ベスローテン フェンノートシャップ 肺気腫及びその他の形態のｃｏｐｄの治療のための組成物及び方法
IT202100021602A1 (it) * 2021-08-09 2023-02-09 Sofar Spa Composizione in forma di polvere secca per inalazione per uso in un metodo di trattamento di un’infiammazione e/o di uno stress ossidativo dell’apparato respiratorio causata/o da inquinamento dell’aria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US6235725B1 (en) * 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
WO2002032406A2 (en) * 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides

Also Published As

Publication number Publication date
WO2003068187A1 (en) 2003-08-21
DK1511466T4 (en) 2015-03-30
HK1074582A1 (en) 2005-11-18
ES2315479T5 (es) 2015-07-01
CA2516318A1 (en) 2003-08-21
CA2516318C (en) 2011-07-19
AU2003207317A1 (en) 2003-09-04
ATE410147T1 (de) 2008-10-15
PT1511466E (pt) 2009-01-16
DK1511466T3 (da) 2009-02-16
ES2315479T3 (es) 2009-04-01
EP1511466B2 (de) 2015-02-25
EP1511466A1 (de) 2005-03-09
EP1511466B1 (de) 2008-10-08

Similar Documents

Publication Publication Date Title
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
DE60318193D1 (en) Phenethanolaminderivate
CY1114728T1 (el) Φαρμακοτεχνικη μορφη εισπνοης περιλαμβανουσα παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
EA200500782A1 (ru) Лечение геморрагического шока
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
HK1074582A1 (en) Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
NO20050063L (no) 2-heteroaryl karboksamider
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ATE359087T1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
NO20076405L (no) Anvendelse av 24-nor-UDCA
IS2613B (is) Útskipt díketópíperasín sem oxýtósínblokkar
ATE526967T1 (de) Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
ATE461696T1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
NO975028L (no) Piperazinoderivater som neurokininantagonister
ATE295838T1 (de) Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen
ATE398134T1 (de) Neue analoga von nitrobenzylthioinosin

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: OCKHAM BIOTECH LTD., SWANWICK, HAMPSHIRE, GB

8363 Opposition against the patent